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Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex and largely unclear pathogenesis. Cellular
phospholipid microvesicles released upon activation and/or death of a cell have been proposed to play a role in inflammatory
autoimmune pathologies, including SLE. Here, circulating microvesicles of various cellular origins were marked with fluores-
cently labeled cell-specific antibodies and enumerated by flow cytometry in platelet-free plasma obtained from the heparinized
blood of 29 SLE patients and 19 normal subjects. Significantly higher concentrations of endothelial-, monocyte-, and
erythrocyte-derived microvesicles were found in the SLE patients compared to normal subjects with prevalence of microvesicles
originating from endothelial cells. No significant difference was found for platelet-derived microvesicles. A correlation analysis
of microvesicle counts with laboratory parameters and clinical features of SLE suggest differential implications of various cell-
derived microvesicles in the pathogenesis of SLE. These data suggest that SLE is associated with functional alterations of
endotheliocytes, monocytes, and erythrocytes followed by enhanced release of microvesicles that may contribute to inflamma-
tion and hypercoagulability.
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1 Introduction
Microvesicles (MVs) are a heterogeneous population of phos-
pholipid vesicles up to about 1μm in size released from various
cells, including blood cells and endothelium, in response to cell
activation, aging, and apoptosis [1]. Circulating MVs can play
an important physiological role in normal conditions [2, 3] as
well as in inflammation, cancer, angiogenesis, thrombosis, etc.
[4]. The blood levels of cell-derived circulatingMVs of various
origins are often increased compared to healthy subjects and
MVs contribute to the pathogenesis of various diseases, includ-
ing inflammatory and autoimmune pathologies [5].
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease that affects multiple tissues and organs, leading
to relatively high morbidity and mortality rates [6]. The patho-
genesis of SLE is complicated and, despite numerous studies,
remains largely unclear [7]. The role ofMVs in themechanisms
of SLE has been a matter of controversy. Some studies reported
elevated levels of circulating MVs in SLE [8], while others
found that the number of MVs in the blood is either unchanged
or even decreased [9]. The cellular origin of circulating MVs as
well as their functional importance in SLE remains vague, al-
though potentially, the content and cellular origins of circulating
MVs may shed light on the pathogenesis of SLE and serve as
biomarkers of disease activity and progression.
The aim of this study was to determine the levels of cell-
derived circulating MVs in SLE patients with respect to their
origin and reveal associations between clinical features and
the levels of circulating MVs.
2 Materials and Methods
2.1 SLE Patients and Healthy Subjects
The study was approved by the Ethical Committee of Kazan
State Medical Academy (Kazan, Russian Federation) and per-
formed in accordance with the Declaration of Helsinki.
Patients with SLE enrolled in this study were from the
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